Szocs Depot Egeszsegugyi Szolgaltato Kft.
- Address
- Jozsef Attila utca 52./1st floor, door 5-6., 1042 Budapest, Hungary
Nutritional and Metabolic Diseases
At Szocs Depot Egeszsegugyi Szolgaltato Kft. in Budapest, the clinical research focus is centered on nutritional and metabolic diseases, especially overweight and obesity and type 2 diabetes. The studies are designed to evaluate whether new treatment approaches can support better weight control and improved blood sugar management for people living with these chronic conditions.
- Research in overweight and obesity and type 2 diabetes
- Testing whether a new therapy can improve body weight reduction
- Evaluating treatment performance for better glycaemic control and weight outcomes
These trials aim to help determine how effectively investigational therapies may work alongside lifestyle changes or standard diabetes care, with the goal of improving everyday disease management.
Type 2 Diabetes Research
The site is also contributing to studies focused specifically on type 2 diabetes, where the main interest is whether new treatment options can lower HbA1c and support meaningful body weight improvement. This area of research compares emerging therapies with established diabetes treatments to better understand their potential benefits for patients who need stronger control of blood sugar.
- Type 2 diabetes treatment optimization
- Assessment of blood sugar lowering and weight effects
- Comparison of new therapies with current diabetes care options
By examining both metabolic and weight-related outcomes, the research aims to support more effective and practical treatment strategies for people with diabetes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szocs Depot Egeszsegugyi Szolgaltato Kft.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin, SGLT2 inhibitor or both | Novo Nordisk A/S | Phase III | Not Recruiting | Oct 2024 | Jul 2026 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 2 | Unknown | 2023-01-30 | 2024-10-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.